Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.
Saved in:
| Title: | Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML. |
|---|---|
| Authors: | Ball BJ; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA. brball@coh.org., Xiao W; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nguyen LXT; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA., Valerio M; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA., Venkatachalam A; The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel., Marcucci G; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA., Stein AS; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA., Thai DL; Edgewood Oncology, Brookline, MA, USA., Cook DN; Edgewood Oncology, Brookline, MA, USA., Chan K; BioTheryx, San Diego, CA, USA., Persaud S; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Levine RL; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Abdel-Wahab O; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ben-Neriah Y; The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel., Stein EM; Memorial Sloan Kettering Cancer Center, New York, NY, USA. steine@mskcc.org. |
| Source: | Journal of hematology & oncology [J Hematol Oncol] 2025 Jul 15; Vol. 18 (1), pp. 73. Date of Electronic Publication: 2025 Jul 15. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
